JPWO2019180658A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019180658A5 JPWO2019180658A5 JP2021500367A JP2021500367A JPWO2019180658A5 JP WO2019180658 A5 JPWO2019180658 A5 JP WO2019180658A5 JP 2021500367 A JP2021500367 A JP 2021500367A JP 2021500367 A JP2021500367 A JP 2021500367A JP WO2019180658 A5 JPWO2019180658 A5 JP WO2019180658A5
- Authority
- JP
- Japan
- Prior art keywords
- hgfr
- human
- antibody fragment
- extracellular portion
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 claims 42
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 40
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 40
- 102000057421 human MET Human genes 0.000 claims 35
- 108020001507 fusion proteins Proteins 0.000 claims 21
- 102000037865 fusion proteins Human genes 0.000 claims 21
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 210000004899 c-terminal region Anatomy 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 4
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 2
- 101000654674 Homo sapiens Semaphorin-6A Proteins 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 102100032795 Semaphorin-6A Human genes 0.000 claims 2
- 230000003042 antagnostic effect Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000003875 | 2018-03-22 | ||
| IT102018000003875A IT201800003875A1 (it) | 2018-03-22 | 2018-03-22 | Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi |
| PCT/IB2019/052307 WO2019180658A1 (en) | 2018-03-22 | 2019-03-21 | Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518170A JP2021518170A (ja) | 2021-08-02 |
| JPWO2019180658A5 true JPWO2019180658A5 (https=) | 2022-02-22 |
| JP2021518170A5 JP2021518170A5 (https=) | 2022-02-22 |
| JP7381555B2 JP7381555B2 (ja) | 2023-11-15 |
Family
ID=62530500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500367A Active JP7381555B2 (ja) | 2018-03-22 | 2019-03-21 | 腫瘍および／または転移の治療のための抗－ｈｇｆｒ抗体およびｈｅｇｆｒの組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11814433B2 (https=) |
| EP (1) | EP3768710A1 (https=) |
| JP (1) | JP7381555B2 (https=) |
| KR (1) | KR20200135449A (https=) |
| CN (1) | CN112041340A (https=) |
| AU (1) | AU2019240274B2 (https=) |
| BR (1) | BR112020018981A8 (https=) |
| CA (1) | CA3093513A1 (https=) |
| IL (1) | IL277476B1 (https=) |
| IT (1) | IT201800003875A1 (https=) |
| MX (1) | MX2020009787A (https=) |
| SG (1) | SG11202008612XA (https=) |
| WO (1) | WO2019180658A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017135251A1 (ja) * | 2016-02-02 | 2017-08-10 | 国立研究開発法人物質・材料研究機構 | 強磁性トンネル接合体、これを用いた磁気抵抗効果素子及びスピントロニクスデバイス並びに強磁性トンネル接合体の製造方法 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025188676A1 (en) * | 2024-03-04 | 2025-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Genetic engineering of cells for secretion of therapeutic antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006018354D1 (de) * | 2005-12-05 | 2010-12-30 | Pfizer Prod Inc | Verfahren zur behandlung von abnormalem zellwachstum |
| CA2638889C (en) * | 2006-02-06 | 2015-06-02 | Metheresis Translational Research S.A. | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| CN101914161B (zh) * | 2010-08-13 | 2013-12-11 | 四川大学 | 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途 |
| ITTO20130012A1 (it) * | 2013-01-09 | 2014-07-10 | Metheresis Translational Res S A | Nuovi frammenti anticorpali, relative composizioni ed usi |
-
2018
- 2018-03-22 IT IT102018000003875A patent/IT201800003875A1/it unknown
-
2019
- 2019-03-21 SG SG11202008612XA patent/SG11202008612XA/en unknown
- 2019-03-21 US US16/982,330 patent/US11814433B2/en active Active
- 2019-03-21 MX MX2020009787A patent/MX2020009787A/es unknown
- 2019-03-21 JP JP2021500367A patent/JP7381555B2/ja active Active
- 2019-03-21 CA CA3093513A patent/CA3093513A1/en active Pending
- 2019-03-21 EP EP19721054.5A patent/EP3768710A1/en active Pending
- 2019-03-21 KR KR1020207030214A patent/KR20200135449A/ko not_active Ceased
- 2019-03-21 CN CN201980020753.XA patent/CN112041340A/zh active Pending
- 2019-03-21 BR BR112020018981A patent/BR112020018981A8/pt unknown
- 2019-03-21 WO PCT/IB2019/052307 patent/WO2019180658A1/en not_active Ceased
- 2019-03-21 AU AU2019240274A patent/AU2019240274B2/en active Active
-
2020
- 2020-09-21 IL IL277476A patent/IL277476B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2857500T3 (es) | Anticuerpo anti-mesotelina y composición que comprende el mismo | |
| JP7606257B2 (ja) | 抗ｃｄ２７６抗体、抗体薬物複合体、及びその使用 | |
| JP7358365B2 (ja) | がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用 | |
| US10047163B2 (en) | Multispecific constructs | |
| BR112020012464A2 (pt) | molécula de ligação ao antígeno biespecífica; proteína de fusão recombinante, receptor de antígeno quimérico, célula, sequência de ácidos nucleicos, vetor, célula hospedeira, método para preparar uma molécula de ligação ao antígeno biespecífica, proteína de fusão recombinante ou receptor de antígeno quimérico, composição farmacêutica, uso de uma molécula de ligação ao antígeno biespecífica, método para tratamento de uma doença em um paciente que necessita de tratamento, método para avaliar a presença de um analito-alvo em uma amostra, método para imageamento de um sítio de doença em um indivíduo, método para diagnóstico de uma doença ou afecção médica em um indivíduo, anticorpo, fragmento de anticorpo ou molécula de ligação ao antígeno, kit e método para diagnóstico de um indivíduo que sofre de câncer, ou uma predisposição para o mesmo, ou para fornecer um prognóstico da afecção de um indivíduo, método para eliminar ou inibir o crescimento de uma célula que expressa ror1 e egfr in vitro ou em um paciente | |
| US11623963B2 (en) | Cysteine engineered antigen-binding molecules | |
| WO2022042719A1 (zh) | 抗vegf-抗pd-l1双特异性抗体、其药物组合物及用途 | |
| BRPI0707824A2 (pt) | proteÍna de ligaÇço a antÍgeno, e, mÉtodos de neutralizaÇço da ativaÇço de um receptor de tirosina quinase, de inibiÇço de angiogÊnese, de reduÇço de crescimento de tumor e de produÇço de uma proteÍna de ligaÇço a antÍgeno | |
| JP2018512124A (ja) | トランスフォーミング増殖因子β１に高親和性、アビディティおよび特異性で結合する修飾ＩｇＧ抗体 | |
| CN115361972A (zh) | 工程化抗her2双特异性蛋白 | |
| WO2022111476A1 (zh) | 抗PD-L1-抗VEGF-抗TGF-β多特异性抗体、其药物组合物及用途 | |
| WO2023109888A1 (zh) | 抗ang2-vegf双特异性抗体及其用途 | |
| JP2021518170A5 (https=) | ||
| CN118922441A (zh) | 全犬抗犬pd-1抗体及其用途 | |
| CN117820478A (zh) | 纳米抗体的串联分子及其在疾病治疗中的用途 | |
| CN114786720A (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| JPWO2019180658A5 (https=) | ||
| CN120187457A (zh) | 配体-细胞毒性药物缀合物及其药物用途 | |
| JP2022504392A5 (https=) | ||
| WO2025140522A1 (en) | Anti-tfr1 antibodies, preparation methods and uses thereof | |
| RU2020129465A (ru) | Комбинация антитела против hgfr и hegfr для лечения опухоли и/или метастаза | |
| WO2026082020A1 (zh) | 双特异性抗体和药物偶联物及其用途 | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| TW202539735A (zh) | 一種包含特異性結合ｄｌｌ３和ｃｄ３的雙特異性抗體的醫藥組成物 | |
| WO2025117871A1 (en) | Bispecific tetravalent antibody targeting her2 and her3 |